The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Slides:



Advertisements
Similar presentations
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Advertisements

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Clofarabine ± Fludarabine with Once Daily i. v
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed.
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Sabina Kersting, Leo F. Verdonck 
Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma  Gaurav C. Parikh, Ali Imran Amjad, Rima.
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962 
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in.
Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation  Joseph Pidala, Claudio.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.
A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia  Lesley J. Ashton, Renate.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma 
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Koji Sasaki, Gary Lu, Rima M. Saliba,
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation  Kazutaka.
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas 
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS  Aaron T. Gerds, Ted A. Gooley,
Gerard Socié, K. Scott Baker, Smita Bhatia 
Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Carlos A. Ramos, Rima.
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer  Kim A. Margolin, James H. Doroshow, Paul Frankel,
Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation 
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J
Once Daily i. v. Busulfan and Fludarabine (i. v
Presentation transcript:

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy  Yee Chung Cheng, Gabriela Rondón, Ying Yang, Terry L. Smith, James L. Gajewski, Michele L. Donato, Elizabeth J. Shpall, Roy Jones, Gabriel N. Hortobagyi, Richard E. Champlin, Naoto T. Ueno  Biology of Blood and Marrow Transplantation  Volume 10, Issue 11, Pages 794-804 (November 2004) DOI: 10.1016/j.bbmt.2004.07.009 Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier overall relapse-free survival curve (all patients). Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier overall survival curve (all patients). Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Kaplan-Meier relapse-free survival curves by preoperative neoadjuvant chemotherapy. Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Kaplan-Meier overall survival curves by preoperative neoadjuvant chemotherapy. Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Kaplan-Meier relapse-free survival curves by disease stage at diagnosis. Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Kaplan-Meier overall survival curves by disease stage of diagnosis. Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 7 Kaplan-Meier relapse-free survival curves by node ratio (number of metastatic axillary nodes divided by the number of nodes removed). Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 8 Kaplan-Meier overall survival curves by node ratio (number of metastatic axillary nodes divided by the number of nodes removed). Biology of Blood and Marrow Transplantation 2004 10, 794-804DOI: (10.1016/j.bbmt.2004.07.009) Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.